DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

MRI Homepage

MR reveals immune cell role in traumatic brain injury repair Repair damaged blood vessels of the meninges

Researchers develop unique 7T MR head coil for better imaging 'Tic-Tac-Toe' shows promise in neurological diseases

CMS eases up on MR requirements for patients with implants Extends coverage to patients with pacemakers, ICDs, CRT-Ps, and CRT-Ds

Avante partners with EMS for CT and MR expertise Combining to offer a more robust portfolio to healthcare providers

Intraoperative MR is improving outcomes at Nicklaus Children's in Miami Insights from pediatric neurosurgeon, Dr. Travis Tierney

NVIDIA aims to bring AI insights to existing global fleet of imaging systems With Project Clara, older scanners may gain remote access to latest capabilities

Machine learning could diagnose SCI neurological impairment, study says Utilizes T2-weighted MR for classification

Siemens selects SAS IoT analytics to manage data from its global install base Aims to maximize uptime for CT, MR and other systems

How to lower breast MR wait times from 101 days to five University of Michigan shares lessons that other facilities can learn from

Bringing the MR suite to the NICU Shaare Zedek Medical Center is raising the bar on newborn diagnostics

FDA to require gadolinium retention label warnings

by Thomas Dworetzky , Contributing Reporter
In the ongoing discussion over gadolinium-based contrast agents, the U.S. Food and Drug Administration (FDA) has now issued a safety communication.

It will require “a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs,” the agency said in a statement.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



No direct link to adverse health impacts have been found in those with normally functioning kidneys, noted the agency, explaining that “we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.”

That said, the added review and talks with the Medical Imaging Drugs Advisory Committee, has led to changes designed to highlight retention issues with MR imaging using GBCA.

These include a new Medication Guide for patients to be read prior to getting a GBCA, as well as requiring makers to perform further animal and human studies over its safety.

The kidneys usually clear the agents, but trace amounts have been found in the body. For those with a higher risk of retention, such as patients who may need multiple doses, those who are pregnant, children and those with inflammatory conditions, the agency advises care, but stressed, “do not avoid or defer necessary GBCA MR scans.”

For those at risk, the FDA pointed out that linear GBCAs “result in more retention and retention for a longer time than macrocyclic GBCAs,” and to give them accordingly.

As a result of its review, stated Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, “we recommend that health care professionals consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk, such as those who may require repeat GBCA MR scans to monitor a chronic condition."

In specific, it stated that body levels of gadolinium are highest with Omniscan (gadodiamide) or OptiMARK (gadoversetamide) compared with Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), or MultiHance (gadobenate dimeglumine). Gadolinium levels are lowest when using Dotarem (gadoterate meglumine), Gadavist (gadobutrol), and ProHance (gadoteridol) – and levels are similar for these agents.

Although the health impact of gadolinium retention has yet to be established, the agency noted that “we are continuing to assess the health effects of gadolinium retention in the body and will update the public when new information becomes available.”
  Pages: 1 - 2 >>

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED